{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:22Z","timestamp":1792790482684,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jaci.2023.09.021","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:41:56Z","timestamp":1695919316000},"page":"161-172.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Correa","family":"Da Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Hassan-Zahraee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.09.021_bib1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2023.09.021_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","article-title":"Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients","volume":"35","author":"Elbuluk","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2023.09.021_bib3","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2023.09.021_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of vitiligo among adults in the United States","volume":"158","author":"Gandhi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/jocd.13459","article-title":"Cosmetic camouflage as an adjuvant to vitiligo therapies: effect on quality of life","volume":"20","author":"Bassiouny","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjd.15199","article-title":"Vitiligo and depression: a systematic review and meta-analysis of observational studies","volume":"177","author":"Lai","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241445","article-title":"Vitiligo and anxiety: a systematic review and meta-analysis","volume":"15","author":"Kussainova","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2023.09.021_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40257-016-0172-x","article-title":"Social anxiety and quality of life in vitiligo and acne patients with facial involvement: a cross-sectional controlled study","volume":"17","author":"Salman","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: an update on pathophysiology and treatment options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Current and emerging treatments for vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for vitiligo: a systematic review and meta-analysis","volume":"153","author":"Bae","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/1346-8138.15858","article-title":"Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: a retrospective study of 58 therapy experiences for 33 vitiligo patients","volume":"48","author":"Wada-Irimada","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/pcmr.12955","article-title":"The fate of melanocyte: mechanisms of cell death in vitiligo","volume":"34","author":"Wu","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2023.09.021_bib16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jdv.14792","article-title":"Critical appraisal of the oxidative stress pathway in vitiligo: a systematic review and meta-analysis","volume":"32","author":"Speeckaert","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.09.021_bib17","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","article-title":"Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.021_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1203475420972340","article-title":"Cutaneous JAK expression in vitiligo","volume":"25","author":"Abdel Motaleb","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2023.09.021_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2019.05.011","article-title":"Oxidative stress\u2013induced IL-15 trans-presentation in keratinocytes contributes to CD8","volume":"139","author":"Chen","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jaci.2023.09.021_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cei\/uxab002","article-title":"Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors","volume":"207","author":"Faraj","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.09.021_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling","volume":"142","author":"Martins","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib25","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.12688\/f1000research.26728.1","article-title":"Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases","volume":"9","author":"Groover","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.jaci.2023.09.021_bib26","article-title":"Comprehensive analysis of cell population dynamics and related core genes during vitiligo development","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.jaci.2023.09.021_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14550","article-title":"Therapeutic options and hot topics in vitiligo with special focus on pediatrics\u2019 vitiligo: a comprehensive review study","volume":"34","author":"Roohaninasab","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2023.09.021_bib28","article-title":"Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo","volume":"5","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2023.09.021_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.09.021_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaci.2023.09.021_bib31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib32","article-title":"The promising role of chemokines in vitiligo: from oxidative stress to the autoimmune response","volume":"2022","author":"He","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jaci.2023.09.021_bib33","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jaci.2023.09.021_bib34","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jaci.2023.09.021_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy\u00a0and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12864-015-2356-9","article-title":"QuickRNASeq lifts large-scale RNA-Seq data analyses to the next level of automation and interactive visualization","volume":"17","author":"Zhao","year":"2016","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jaci.2023.09.021_bib37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jaci.2023.09.021_bib38","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and\u00a0biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.021_bib39","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Suarez-Farinas","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.021_bib40","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2023.09.021_bib41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/2047487316676134","article-title":"Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria","volume":"24","author":"Carlsson","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jaci.2023.09.021_bib42","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"Voom: precision weights unlock linear model analysis tools for RNA-Seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.jaci.2023.09.021_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.021_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0019-5154.92668","article-title":"Serum concentration of IL-6, IL-2, TNF-\u03b1, and IFN\u03b3 in Vitiligo patients","volume":"57","author":"Singh","year":"2012","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib45","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jocd.13908","article-title":"Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity","volume":"20","author":"Atwa","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0923-1811(99)00029-8","article-title":"Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo","volume":"21","author":"Caixia","year":"1999","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.09.021_bib47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0923-1811(98)00070-X","article-title":"Serum concentration of the soluble interleukin-2 receptor in vitiligo patients","volume":"19","author":"Yeo","year":"1999","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.09.021_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/35051100","article-title":"ICOS co-stimulatory receptor is essential for T-cell activation and function","volume":"409","author":"Dong","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.09.021_bib49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00403-019-01996-9","article-title":"Predominant role of innate pro-inflammatory cytokines in vitiligo disease","volume":"312","author":"Gholijani","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2023.09.021_bib50","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamadermatol.2020.0218","article-title":"Evaluation for skin cancer and precancer in patients with vitiligo treated with long-term narrowband UV-B phototherapy","volume":"156","author":"Bae","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib52","article-title":"Networks of CD8","volume":"13","author":"Fukuda","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.09.021_bib53","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.09.021_bib54","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomized, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.09.021_bib55","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923012022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923012022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:46:09Z","timestamp":1758793569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923012022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0091674923012022"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.09.021","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}